London, June 8, 2026, 14:12 BST
Oxford Instruments shares edged lower on Monday afternoon as investors held back before Tuesday’s preliminary results, despite a new semiconductor-characterisation collaboration that put its chip tools back in focus. The FTSE 250 stock was quoted at 3,060p to sell and 3,064p to buy, down 4p, or 0.13%, at 13:54 BST; Barclays data also showed the FTSE 250 down 0.18%, giving the move a slightly weaker mid-cap backdrop.
This matters now because the stock is already close to the top of its range. AJ Bell data put Oxford Instruments’ year high at 3,330.61p, year low at 1,682p and market value at about 1.69 billion pounds, leaving less space for a routine in-line update to excite buyers.
Oxford Instruments’ own calendar lists June 9 for the announcement of preliminary results. That gives Monday’s trading a simple shape: investors are waiting for hard numbers and guidance, not just another industrial technology headline.
The company supplies scientific tools and systems used by industry and research customers, with exposure to materials analysis, semiconductors and healthcare and life science. That mix has become more closely watched as investors try to separate durable demand for chip and quantum-related equipment from the more volatile parts of the technology cycle.
The fresh news came from Covalent, which announced a strategic collaboration using Oxford Instruments’ WITec360 Raman technology for wafer-level semiconductor work. Raman and photoluminescence, often shortened to PL, are light-based tests that help read defects, stress and material properties without destroying a wafer; Covalent CEO Craig Hunter said the aim was to broaden what customers can do, “not just what we can measure,” while Oxford Instruments’ Vahan Tchakerian said the work helps “bridge the gap from R&D to high-volume production.” Oxford Instruments
The partnership is tied to silicon carbide and gallium nitride, materials used in higher-performance power and radio-frequency chips. The commercial question is less whether the technology is useful, and more how fast such applications turn into orders, revenue and margin.
Analysts go into the results with company-compiled consensus looking for FY26 revenue of 420.7 million pounds and adjusted EBIT of 71.3 million pounds. EBIT means earnings before interest and tax, a profit measure before financing costs and taxes; “adjusted” means the company is stripping out items it does not treat as part of normal trading. Oxford Instruments
Valuation is the rub. Investors Chronicle data from LSEG showed six analysts with a median 12-month target price of 2,695p, with a high estimate of 3,000p and a low estimate of 2,300p, below the last price of 3,062p shown in that dataset. The same data showed five “outperform” ratings and three “hold” ratings, with no sells. Investors Chronicle
The peer read-across was mixed. Renishaw, another UK engineering technology group supplying measuring and production systems, was down 1.24%, while Judges Scientific, an AIM-quoted scientific-instrument group, rose 2.37%; that does not point to a clean sector-wide move against instrument makers.
But the risk is clear. Oxford Instruments’ April trading update rested on a stronger second half, cost actions at its Belfast imaging business and Advanced Technologies order growth of about 30% on an organic constant currency basis — meaning growth excluding currency swings and portfolio effects; if those orders do not convert cleanly into FY27 revenue, or if margin gains disappoint, a stock trading near its 52-week high could find sellers quickly. CEO Richard Tyson said then the group was “well positioned for growth,” but Tuesday’s numbers must carry that line. Investegate
For now, the shares are not reacting much to the Covalent announcement. The bigger test is one day away.
